OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Chronic Obstructive Pulmonary Disease (COPD)

Submission Deadline: August 30, 2021 (Open) Submit Now

Guest Editor

Isaac K. Sundar, PhD

Associate Professor, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas Medical Center, USA


Research Interests: Lung Inflammation; oxidative stress; chronic obstructive pulmonary disease (COPD); mitochondrial dysfunction; lung cellular senescence; circadian rhythms, extracellular vesicle/exosomes

About This Topic

Chronic obstructive pulmonary disease (COPD) is among the top 3 leading causes of death worldwide next to coronary heart disease and stroke. This chronic inflammatory lung disease is characterized by abnormal inflammation and tissue injury that primarily affects the small airways and results in emphysema (alveolar destruction of the lungs). Several different lung cell types have been shown to play an important role in the pathobiology of this chronic lung aging disease/COPD. In this special issue entitled “Chronic Obstructive Pulmonary Disease (COPD)” we focus to cover all the emerging approaches that basic, clinical translational science researchers undertake to address the pressing need in understanding the pathobiology of COPD to develop novel ways for the treatment and management of lung aging disease/COPD. We invite both early-stage investigators, mid-career, and established investigators in the field of COPD to submit their findings in the form of research articles, updated reviews/perspectives, editorials, case reports, and short communications in the broad area of COPD. This will include research studies utilizing cell culture models, primary human cells and tissues, animal models of COPD, genomics, and epigenomic analyses of existing datasets with further validation including clinical case reports, epidemiological studies, meta-analysis, etc. but not limited to. As a member of the editorial board and editor of this special issue, we hope the readers will find these publications to be of great interest to the readers and scientific community in the field of lung aging and COPD.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!